Anthrax toxin receptor proteins

Biochemical Pharmacology

Volumn 65, Issue 3, 2003, Pages 309-314

  Bradley, Kenneth A ^a,b,c   Young, John A T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Anthrax toxin; Antitoxin; ATR; Receptor; TEM8

Indexed keywords

ANTHRAX TOXIN; ANTIBIOTIC AGENT; ANTITOXIN; CELL RECEPTOR; INTEGRIN; MEMBRANE PROTEIN; RECEPTOR PROTEIN; RECEPTOR SUBUNIT; TUMOR MARKER; VIRULENCE FACTOR;

ANGIOGENESIS; ANTHRAX; BACTERIAL CELL; BACTERIUM CULTURE; BINDING SITE; CELL PROTECTION; DRUG EFFECT; GENETIC CODE; HUMAN; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0037300719     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01455-7     Document Type: Note

References (55)

1. Dixon T.C., Meselson M., Guillemin J., Hanna P.C. Anthrax. N Engl. J. Med. 341:1999;815-826.
2. Keppie J., Smith H., Harris-Smith P.W. The chemical basis of the virulence of Bacillus anthracis. II: some biological properties of bacterial products. Br. J. Exp. Pathol. 34:1953;486-496.
3. Green B.D., Battisti L., Koehler T.M., Thorne C.B., Ivins B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:1985;291-297.
4. Mikesell P., Ivins B.E., Ristroph J.D., Dreier T.M. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun. 39:1983;371-376.
5. Uchida I., Sekizaki T., Hashimoto K., Terakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J. Gen. Microbiol. 131(Pt 2):1985;363-367.
6. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U.S.A. 79:1982;3162-3166.
7. O'Brien J., Friedlander A., Dreier T., Ezzell J., Leppla S. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47:1985;306-310.
8. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., Vande Woude G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 280:1998;734-737.
9. Vitale G., Pellizzari R., Recchi C., Napolitani G., Mock M., Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:1998;706-711.
10. Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352(Pt 3):2000;739-745.
11. Hanna P.C., Acosta D., Collier R.J. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10198-10201.
12. Hanna P.C., Kruskal B.A., Ezekowitz R.A., Bloom B.R., Collier R.J. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol. Med. 1:1994;7-18.
13. Watters J.W., Dewar K., Lehoczky J., Boyartchuk V., Dietrich W.F. Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor. Curr. Biol. 11:2001;1503-1511.
14. Tang G., Leppla S.H. Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect. Immun. 67:1999;3055-3060.
15. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:1995;82-87.
16. Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:1994;20607-20612.
17. Mogridge J., Cunningham K., Collier R.J. Stoichiometry of anthrax toxin complexes. Biochemistry. 41:2002;1079-1082.
18. Friedlander A.M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:1986;7123-7126.
19. Milne J.C., Collier R.J. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10:1993;647-653.
20. Escuyer V., Collier R.J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:1991;3381-3386.
21. Friedlander AM, Raziuddin A. Anthrax protective antigen receptor: identification of a protective antigen binding protein by chemical cross-linking. In: Withholdt B, editor. Bacterial protein toxins. New York: Gustav Fischer; 1992, p. 365-6.
22. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A. Identification of the cellular receptor for anthrax toxin. Nature. 414:2001;225-229.
23. St. Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
24. Dickeson S.K., Santoro S.A. Ligand recognition by the I domain-containing integrins. Cell Mol. Life Sci. 54:1998;556-566.
25. Smith H., Keppie J. Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature. 173:1954;869-870.
26. Brossier F., Levy M., Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70:2002;661-664.
27. Kobiler D., Gozes Y., Rosenberg H., Marcus D., Reuveny S., Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:2002;544-560.
28. Mourez M., Kane R.S., Mogridge J., Metallo S., Deschatelets P., Sellman B.R., Whitesides G.M., Collier R.J. Designing a polyvalent inhibitor of anthrax toxin. Nat. Biotechnol. 19:2001;958-961.
29. Sellman B.R., Mourez M., Collier R.J. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science. 292:2001;695-697.
30. Gordon V.M., Leppla S.H., Hewlett E.L. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1988;1066-1069.
31. Koehler T.M., Collier R.J. Anthrax toxin protective antigen: low-pH-induced hydrophobicity and channel formation in liposomes. Mol. Microbiol. 5:1991;1501-1506.
32. Ménard A., Altendorf K., Breves D., Mock M., Montecucco C. The vacuolar ATPase proton pump is required for the cytotoxicity of Bacillus anthracis lethal toxin. FEBS Lett. 386:1996;161-164.
33. Blaustein R.O., Koehler T.M., Collier R.J., Finkelstein A. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. U.S.A. 86:1989;2209-2213.
34. Finkelstein A. The channel formed in planar lipid bilayers by the protective antigen component of anthrax toxin. Toxicology. 87:1994;29-41.
35. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature. 385:1997;833-838.
36. Beauregard K.E., Collier R.J., Swanson J.A. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell Microbiol. 2:2000;251-258.
37. Singh Y., Klimpel K.R., Goel S., Swain P.K., Leppla S.H. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect. Immun. 67:1999;1853-1859.
38. Naglich J.G., Metherall J.E., Russell D.W., Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell. 69:1992;1051-1061.
39. Almond B.D., Eidels L. The cytoplasmic domain of the diphtheria toxin receptor (HB-EGF precursor) is not required for receptor-mediated endocytosis. J. Biol. Chem. 269:1994;26635-26641.
40. Novak J.M., Stein M.-P., Little S.F., Leppla S.H., Friedlander A.M. Functional characterization of protease-treated Bacillus anthracis protective antigen. J. Biol. Chem. 267:1992;17186-17193.
41. Beauregard K.E., Wimer-Mackin S., Collier R.J., Lencer W.I. Anthrax toxin entry into polarized epithelial cells. Infect. Immun. 67:1999;3026-3030.
42. Molloy S.S., Anderson E.D., Jean F., Thomas G. Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol. 9:1999;28-35.
43. Klimpel K.R., Molloy S.S., Thomas G., Leppla S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10277-10281.
44. Molloy S.S., Bresnahan P.A., Leppla S.H., Klimpel K.R., Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem. 267:1992;16396-16402.
45. Leppla SH. Anthrax toxin. In: Aktories K, Just I, editors. Handbook of experimental pharmacology. Berlin: Springer; 2000, p. 447-72.
46. Fritz G., Schroeder P., Aktories K. Isolation and characterization of a Clostridium botulinum C2 toxin-resistant cell line: evidence for possible involvement of the cellular C2II receptor in growth regulation. Infect. Immun. 63:1995;2334-2340.
47. Eckhardt M., Barth H., Blocker D., Aktories K. Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. J. Biol. Chem. 275:2000;2328-2334.
48. Jones E.Y., Harlos K., Bottomley M.J., Robinson R.C., Driscoll P.C., Edwards R.M., Clements J.M., Dudgeon T.J., Stuart D.I. Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 Å resolution. Nature. 373:1995;539-544.
49. Main A.L., Harvey T.S., Baron M., Boyd J., Campbell I.D. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell. 71:1992;671-678.
50. Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., St. Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61:2001;6649-6655.
51. Bell S.E., Mavila A., Salazar R., Bayless K.J., Kanagala S., Maxwell S.A., Davis G.E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 114:2001;2755-2773.
52. Duesbery N.S., Resau J., Webb C.P., Koochekpour S., Koo H.M., Leppla S.H., Vande Woude G.F. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc. Natl. Acad. Sci. U.S.A. 98:2001;4089-4094.
53. Liu S., Bugge T.H., Leppla S.H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. 276:2001;17976-17984.
54. Liu S., Netzel-Arnett S., Birkedal-Hansen H., Leppla S.H. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 60:2000;6061-6067.
55. Knodler L.A., Celli J., Finlay B.B. Pathogenic trickery: deception of host cell processes. Nat. Rev. Mol. Cell Biol. 2:2001;578-588.